Full Papers
Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study
E. Bozzalla-Cassione1, G. Zanframundo2, A. Biglia3, E. Bellis4, S. Bozzini5, V. Codullo6, V. Vertui7, C. Alpini8, A. Valentini9, L. Preda10, C. Montecucco11, F. Meloni12, L. Cavagna13
- Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET. emanuele.bozzalla@gmail.com
- Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.
- Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.
- Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.
- Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.
- Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.
- Lung Transplant Centre Unit, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
- Laboratory of Biochemical-Clinical Analyses, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
- Radiology Unit, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
- Radiology Unit, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
- Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.
- Lung Transplant Centre Unit, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
- Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation, Pavia; Chair of Rheumatology, Department of Internal Medics and Therapeutics, University of Pavia, Italy. European Reference Network ReCONNET.
CER15315
2022 Vol.40, N°5 ,Suppl.134
PI 0027, PF 0031
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 35349417 [PubMed]
Received: 07/11/2021
Accepted : 07/03/2022
In Press: 18/03/2022
Published: 18/05/2022
Abstract
OBJECTIVES:
Although antisynthetase antibodies (ARS) are the established markers of the so-called antisynthetase syndrome (ASSD), in these patients the concomitant positivity of anti-Ro52 antibodies, reported in up to the 50% of cases, is not rare. Several studies focused on the effect of different ARS specificities on the evolution of ASSD, the most recent showing no effects. On the contrary, the role of co-occurring anti-Ro52 antibodies in ASSD is still debated. We investigated the potential of anti-Ro52 antibodies in identifying a clinical phenotype of ASSD or influencing prognosis, irrespectively to the underlying ARS specificity.
METHODS:
Retrospective analysis of clinical, imaging and laboratory characteristics, therapeutic approaches and outcome at baseline and at last follow-up, of 60 ASSD patients progressively enrolled at our Hospital.
RESULTS:
We identified 34 anti-Ro+ and 26 anti-Ro- ASSD patients. Classic triad prevalence at baseline was similar between the two groups, whereas interstitial lung disease (ILD) (p value=0.01) and myositis (p value=0.03) were significantly more prevalent in anti-Ro52+ and in anti-Ro52- patients at last follow up, respectively. No differences in therapeutic approaches, oxygen need and ILD patterns were observed. Overall mortality was 25% (15 subjects). No differences in mortality, overall and disease related, between anti-Ro52+ and anti-Ro52- patients were observed (p value=0.764), despite the more frequent ILD occurrence in anti-Ro52+ patients. Survival curves were not different at any time point (Log-rank test, p value 0.98).
CONCLUSIONS:
Anti-Ro52 antibodies affect time course and clinical characteristics of ASSD. Although ILD is significantly more associated to anti-Ro52 antibodies, no difference in mortality was observed compared to anti-Ro52 negative patients.
